Romiti R, Valenzuela F, Chouela EN, Xu W, Pangallo B, Moriarty SR, Gürbüz S, Riedl E
Icon for Wiley Related Articles

Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: Integrated safety analysis from 11 clinical trials of patients with plaque psoriasis.

Br J Dermatol. 2019 Jan 04;:

Authors: Romiti R, Valenzuela F, Chouela EN, Xu W, Pangallo B, Moriarty SR, Gürbüz S, Riedl E

Abstract
Tuberculosis (TB) is one of the top ten causes of death worldwide, with approximately 10.0 million active TB cases in 2017 (range 9.0 to 11.1 million) occurring in all countries and age groups and estimates of 1.7 billion people having latent TB infection (LTBI). The lifetime risk for reactivation of LTBI is 5% to10%, and certain immunosuppressant therapies increase this risk. Data on TB risk following anti-interleukin (IL)-17A treatment in humans are limited, with no cases of LTBI reactivation reported thus far. This article is protected by copyright. All rights reserved.

PMID: 30609008 [PubMed - as supplied by publisher]